Vivos Therapeutics (VVOS) EBITDA (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of EBITDA data on file, last reported at -$6.6 million in Q1 2026.

• On a quarterly basis, EBITDA fell 68.84% year-over-year to -$6.6 million in Q1 2026; TTM through Mar 2026 was -$22.6 million, a 99.88% decrease from a year earlier, with the FY2025 full-year figure at -$19.9 million, down 78.09% from the prior year.
• EBITDA for Q1 2026 stood at -$6.6 million, down from -$6.4 million in the prior quarter.
• Over the last five years, EBITDA for VVOS reached as high as -$1.9 million in Q2 2024 and fell as low as -$7.0 million in Q2 2022.
• Historically, EBITDA has averaged -$4.7 million across 5 years, with a median of -$4.7 million in 2025.
• Across the five-year window, EBITDA surged 57.14% in 2024 and sank 151.29% in 2025, its largest moves.
• Year by year, EBITDA stood at -$6.1 million in 2022, then jumped by 31.83% to -$4.1 million in 2023, then soared by 32.11% to -$2.8 million in 2024, then tumbled by 127.44% to -$6.4 million in 2025, then dropped by 3.65% to -$6.6 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$6.6 million in Q1 2026, -$6.4 million in Q4 2025, and -$4.7 million in Q3 2025.